Clinical trials: Bladder Cancer Recurrence
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fluorouracil given as a continuous infusion in treating…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00003175
- Testing
- fluorouracil
- Where
- 62 sites in Brazil, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Medical Research Council
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
Phase II trial to study the effectiveness of combining trastuzumab with combination chemotherapy in treating patients who have locally recurrent or metastatic urinary tract cancer.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder
- Trial name
- NCT00005831
- Testing
- trastuzumab, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study
The primary objective of this prospective, single-centre study is to establish the clinical performance characteristics of Xpert Bladder Cancer Monitor on the GeneXpert Instrument Systems in comparison to the methods currently…
- Trial name
- NCT03715660
- Testing
- Xpert bladder cancer monitor
- Where
- Egypt
- Volunteers
- 198 people
- Sponsor
- Mansoura University
Melanoma, Solid Tumor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions…
- Conditions
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification
- Trial name
- NCT04985604
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Recurrent Bladder Cancer, Stage 0 Bladder Cancer
Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer
This randomized clinical trial studies intracorporeal or extracorporeal urinary diversion during robotic assisted radical cystectomy in reducing complications in patients with bladder cancer.
- Conditions
- Recurrent Bladder Cancer, Stage 0 Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer
- Trial name
- NCT02252393
- Testing
- robot-assisted laparoscopic surgery, intraoperative complication management/prevention, quality-of-life assessment
- Sponsor
- Case Comprehensive Cancer Center
Superficial Bladder Cancer t1a
Skipping BCG for T1a Urinary Bladder Tumor.
Bladder cancer is the most common malignancy involving theurinary system and the ninth most common malignancy worldwide .In Egypt, the urinary bladder cancer accounted for about 31% of the total incidence of cancers that…
- Trial name
- NCT04298073
- Volunteers
- 43 people
- Sponsor
- Assiut University
Recurrent Superficial Bladder Cancer, Distilled Water
Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection
The purpose of this study is to compare and evaluate the efficacy of distilled water vs Mitomycin C on preventing the recurrences of intermediate risk group recurrent superficial bladder cancer administered as a single dose…
- Trial name
- NCT00816075
- Testing
- distilled water
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Bozyaka Training and Research Hospital